NATCO Pharma Limited (NSE:NATCOPHARM)
India
· Delayed Price · Currency is INR | Market Cap | 170.71B |
| Revenue (ttm) | 45.63B |
| Net Income (ttm) | 15.57B |
| Shares Out | 179.11M |
| EPS (ttm) | 86.94 |
| PE Ratio | 10.96 |
| Forward PE | 20.19 |
| Dividend | 5.00 (0.52%) |
| Ex-Dividend Date | Feb 18, 2026 |
| Volume | 2,953,208 |
| Average Volume | 2,740,956 |
| Open | 958.80 |
| Previous Close | 953.10 |
| Day's Range | 958.80 - 1,003.90 |
| 52-Week Range | 726.80 - 1,059.00 |
| Beta | 0.19 |
| RSI | 63.84 |
| Earnings Date | Feb 12, 2026 |
About NATCO Pharma
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products... [Read more]
Financial Performance
In fiscal year 2025, NATCO Pharma's revenue was 44.32 billion, an increase of 10.74% compared to the previous year's 40.02 billion. Earnings were 18.85 billion, an increase of 35.81%.
Financial StatementsNews
Pharma sector stocks surge today, March 5: Natco Pharma jumps 3.35%, Granules India up 2.74%, Alembic surge nearly 2%
Pharmaceutical stocks in India showed mixed performance on March 5, 2026, during early trading hours, with many recording modest gains amid broader market movements. The S&P BSE HEALTHCARE Index stood...
Natco Pharma shares rise over 2% after launch of generic Pomalidomide Capsules in the US
Shares of Natco Pharma moved higher in early trade on Wednesday after the pharmaceutical company announced the launch of Pomalidomide Capsules in the United States in partnership with Breckenridge Pha...
Natco Pharma launches Generic Pomalidomide Capsules in US market
Natco Pharma Limited (BSE: 524816 | NSE: NATCOPHARM) has announced the launch of Pomalidomide Capsules in the United States in...
Pharma sector stocks down today, March 2: Morepen Lab falls 3.24%, Ajanta Pharma drops 2.32%, Natco Pharma down 2.26%
The Indian pharmaceutical sector experienced a sharp decline on March 2, 2026, with many stocks trading lower in early sessions....
Pharma sector stocks today, Feb 27: Dr. Reddys Lab down 1.14%, Cipla falls 1.04%, Natco Pharma up 1.09%
The Indian pharmaceutical sector showed mixed performance on February 27, 2026, during early morning trading hours. Data from around 9:24...
NATCO Pharma clarifies on Semaglutide launch plans; says no material impact from Eris partnership news
NATCO Pharma has issued a clarification to the stock exchanges regarding a news article related to its Semaglutide product and...
Eris Lifesciences partners with Natco Pharma to launch Semaglutide in India
Eris Lifesciences Limited has entered into a strategic partnership with Natco Pharma Limited for the commercialisation of semaglutide in India,...
Pharma sector stocks today, Feb 19: Natco Pharma jumps 3.98%, Akums Drugs up 2.52%, Senores Pharma surge 2%
The Indian pharmaceutical sector showed modest movement on February 19, 2026, in early trading hours. The S&P BSE HEALTHCARE Index...
Pharma sector stocks today, Feb 18: Cohance Lifesciences surge 5.78%, Jubilant Industries down 4%, Natco Pharma falls 1.78%,
The pharmaceutical sector in India showed modest movement on February 18, 2026, during early trading hours. The S&P BSE HEALTHCARE...
Why are NATCO Pharma shares up over 9% today: Explained
Shares of NATCO Pharma Limited rallied more than 9% after the company received approval from the Central Drugs Standard Control...
NATCO Pharma gets CDSCO approval for Generic Semaglutide Injection, launch set for March 2026
NATCO Pharma Limited (BSE: 524816 | NSE: NATCOPHARM) has received approval from the Central Drugs Standard Control Organization (CDSCO) to...
Natco Pharma Ltd (BOM:524816) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Natco Pharma Ltd (BOM:524816) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
Q3 2026 Natco Pharma Ltd Earnings Call Transcript
Q3 2026 Natco Pharma Ltd Earnings Call Transcript
Natco Pharma receives USFDA EIR for Chennai API unit; Inspection classified as VAI
Natco Pharma Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for...
Natco Pharma Q3 Results: Revenue jumps 36.3% YoY to Rs 647.3 crore, net profit up 14.3%
Natco Pharma reported a mixed set of numbers for the third quarter ended December 31, 2025, with strong revenue growth...
Pharma sector stocks today, Jan 30: Aurobindo Pharma jumps 3%, Ajanta Pharma up 2%, Natco Pharma rises 2%
The Indian pharma sector stocks showed mixed performance on January 30, 2026, as of approximately 10:31 AM IST. The sector...
Pharma sector stocks today, Jan 27: Syngene down 7%, Natco Pharma falls 2.31%, Alembic Pharma down 1%
Pharma stocks showed mixed movement in early trade today with selective buying in mid and small-cap names while several large-cap...
Pharma sector stocks today: Natco Pharma jumps 1.24%, Dr. Reddy’s Lab gain 0.32%, Divi’s Laboratories up 0.14%
The Indian pharmaceutical sector showed mixed performance on January 9, 2026, amid a slightly declining broader market. As of approximately...
Natco Pharma shares rise over 4% as expansion strategy boosts investor sentiment
Shares of Natco Pharma climbed more than 4% to ₹916.35 on Monday as the company’s ongoing expansion across key emerging...
NATCO Pharma concludes US FDA inspection at Chennai API unit, receives seven form 483 observations
NATCO Pharma Limited has confirmed the successful completion of a US FDA inspection at its Active Pharmaceutical Ingredients (API) manufacturing...
Natco Pharma Ltd (BOM:524816) Q2 2026 Earnings Call Highlights: Strategic Wins and Future ...
Natco Pharma Ltd (BOM:524816) Q2 2026 Earnings Call Highlights: Strategic Wins and Future Growth Prospects
Q2 2026 Natco Pharma Ltd Earnings Call Transcript
Q2 2026 Natco Pharma Ltd Earnings Call Transcript
NATCO Pharma Q2 Results: Net profit drops 23% YoY to Rs 518 crore, revenue flat at Rs 1,363 crore
NATCO Pharma reported a steady performance in its Q2 FY26 numbers, with a mix of moderate revenue growth and softer...
NATCO Pharma launches Generic Everolimus Tablets 1mg in the U.S. market
NATCO Pharma Limited has announced the launch of Everolimus Tablets 1mg, a generic version of Zortress® by Novartis, under the...
Pharma expansion: Natco to acquire major stake in South Africa’s Adcock Ingram, firm to go private
Indian firm Natco Pharma is set to acquire substantial stakes in South African pharmaceutical company Adcock Ingram. This deal, valued at R4.2 billion, will transition Adcock Ingram into a privately h...